|
|
| | YLIU-4-105-1 Basic information |
| Product Name: | YLIU-4-105-1 | | Synonyms: | YLIU-4-105-1;Benzamide, 3-[2-[(cyclopropylcarbonyl)amino]imidazo[1,2-b]pyridazin-6-yl]-N-[3-[(4-ethyl-1-piperazinyl)methyl]-5-(trifluoromethyl)phenyl]-4-methyl-;3-(2-(Cyclopropanecarboxamido)imidazo[1,2-b]pyridazin-6-yl)-N-(3-((4-ethylpiperazin-1-yl)methyl)-5-(trifluoromethyl)phenyl)-4-methylbenzamide | | CAS: | 2417685-83-5 | | MF: | C32H34F3N7O2 | | MW: | 605.65 | | EINECS: | | | Product Categories: | | | Mol File: | 2417685-83-5.mol |  |
| | YLIU-4-105-1 Chemical Properties |
| density | 1.397±0.14 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted) | | pka | 9.451±0.20(predicted) |
| | YLIU-4-105-1 Usage And Synthesis |
| Uses | YLIU-4-105-1 is a Type II JAK2 inhibitor. YLIU-4-105-1 binds to the ATP-binding pocket of JH1. YLIU-4-105-1 has in vivo pharmacodynamic activity as evidenced by inhibiting pSTAT5, reducing spleen to body weight, and lowering blood reticulocyte counts in a dose-dependent manner[1]. | | IC 50 | JAK2 | | References | [1] Arwood ML, et al. New scaffolds for type II JAK2 inhibitors overcome the acquired G993A resistance mutation. Cell Chem Biol. 2023 Jun 15;30(6):618-631.e12. DOI:10.1016/j.chembiol.2023.05.007 |
| | YLIU-4-105-1 Preparation Products And Raw materials |
|